Title : Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Pub. Date : 2019 Jan 15

PMID : 30644981






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Conclusions and Relevance: Among patients with relapsing-remitting MS, initial treatment with fingolimod, alemtuzumab, or natalizumab was associated with a lower risk of conversion to secondary progressive MS vs initial treatment with glatiramer acetate or interferon beta. Fingolimod Hydrochloride interferon beta 1 Homo sapiens